Dossier overview
4
research areas
3
references
3
handling notes
01
Mechanism of action
Tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) . The combined incretin activity is associated with improved glycaemic control and substantial weight reduction in clinical trials.
02
Research applications
- Type 2 diabetes glycaemic-control clinical research
- Obesity and weight-management clinical research
- Incretin pharmacology
- Cardiometabolic outcome research
Evidence at a glance
What's behind this profile
3 citations · 2021–2023
- Human
- 3
Studies in human volunteers or patients (incl. early-phase trials).
Publication years
- 21
- 22
- 23
Counts are derived from the cited studies below. A study covering both in vivo and in vitro work is counted by its primary model. Sample size is reported in 3 of 3 citations. Findings remain model-specific and are not extrapolated to therapeutic use.
03
Study references
Each profile cites a minimum of two peer-reviewed sources, with model type and reported sample size where the source provides it. Findings are model-specific and must not be extrapolated to therapeutic use.
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1)
2021
Rosenstock J et al. · The Lancet
- Model
- Phase 3 double-blind randomised placebo-controlled trial in adults with type 2 diabetes
- Sample
- n=478
Tirzepatide monotherapy was associated with superior glycaemic control and weight reduction versus placebo, with a safety profile broadly consistent with GLP-1 .
Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
2022
Jastreboff AM et al. · New England Journal of Medicine
- Model
- Phase 3 double-blind randomised placebo-controlled trial in adults with obesity (without type 2 diabetes)
- Sample
- n=2539
Over 72 weeks, tirzepatide was associated with mean body weight reductions of approximately 15–21% across doses versus 3% with placebo; gastrointestinal adverse events were the most common.
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2)
2023
Garvey WT et al. · The Lancet
- Model
- Phase 3 double-blind randomised placebo-controlled trial in adults with obesity and type 2 diabetes
- Sample
- n=938
Tirzepatide 10–15 mg weekly was associated with mean body weight reductions of 12.8–14.7% over 72 weeks versus 3.2% with placebo, with a safety profile similar to other incretin agents.
Evidence caveats
- FDA approval covers specific indications (T2D, chronic weight management with eligibility criteria). Clinical use is a medical decision with a qualified healthcare professional.
- Long-term cardiovascular and oncologic outcome trials are ongoing; this profile summarises the primary registrational evidence as published.
04
Storage and handling
Approved product follows manufacturer cold-chain instructions. Research-grade material must be stored under controlled laboratory conditions per protocol.
- Approved product follows the manufacturer label and pharmacy cold-chain.
- Research-grade material requires controlled laboratory storage and full batch documentation.
- Clinical use of approved product is exclusively a medical decision made with a healthcare professional.